An observational study in Sickle Cell Disease, Macula Thickening and Macula Abnormality, sponsored by Christophe Orssaud. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Christophe Orssaud · Observational
To investigate retrospectively the longitudinal evolution of vascular defects in patients with typical or atypical forms of SCM.
Several questions regarding this SCM are still unsolved. Its physio pathogenic mechanisms are not clearly understood. In addition, the mean age of onset and the evolution of these retinal and vascular defects have not been fully studied. Recently, "atypical" forms of SCM have been reported, in which there are areas of reduction or disappearance of retinal vascularization at the level of the superficial and deep plexuses but without retinal atrophy on OCT. At last, it remains unclear whether SCM evolved over time or remained stable with age The investigators will retrospectively analyze the longitudinal evolution of vascular defects and retinal thickness in typical or atypical forms of SCM using OCT and OCT-A images. OCT-A images will be processed using the AngioTool64 software to obtain vascular density in SCP and DCP. A 5% variation in vascular density will be considered as significant, regardless of its direction.
1,125 studies on the registry are indexed under Anemia, Sickle Cell; 239 are open to participants now.
This study's enrollment of 34 is below the median of 100 across 295 observational studies indexed under Anemia, Sickle Cell.
Browse Anemia, Sickle Cell studies →This is the only study on the registry with Christophe Orssaud as lead sponsor.
Counted across the registry records on this site, refreshed daily.
A single ophthalmological department the data of adult patients that underwent macular OCT-A at different ophthalmological assessments
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
eyes with thinning of the inner retinal layers with a reduction of vascular flow in both superficial capillary plexuses and deep capillary plexuses
Eyes with an absence retinal atrophy on OCT in territories of reduction or disappearance of retinal vascularization in both superficial capillary plexuses and deep capillary plexuses
Vascular density
Measure vascular density in the superficial and deep plexuses of the same patient over time
Time frame: From january 2020 to January 2026
Macular thickness
Analyze of the macular thickness on OCT
Time frame: From january 2020 to January 2026
Plan to share: Undecided — Need to be in accordance with legal national reglementation
Ran from Sep 2026 to primary completion in Sep 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.